Glycocalyx degradation in sickle cell disease

Glycocalyx degradation in sickle cell disease

• Autor
• Simone Regina Potje
• Co-autores
• Gomes, M.T. , Prohaska, C.C. , Carneiro, A.B. , Machado, R.F.
• Resumo

•  

  Introduction: Sickle cell disease (SCD) is a genetic disorder that promotes pulmonary complications and endothelial dysfunction. The glycocalyx contributes to vascular homeostasis and its degradation is directly associated with endothelial dysfunction. The aim of this study is to evaluate the structure of glycocalyx in SCD in vitro and in vivo models.

  Methods: Sixty-day-old SCD and wild-type (control) mice were used in this study. In addition, pulmonary artery endothelial cells (PAECs) treated with Hemin (10 µM, 20 µM or 40 µM) for different times (3h, 24h or 48h) were used to simulate the effect of hemolysis in the endothelium. We performed Western blot assay to verify the expression of Glypican-1 and Syndecan-1, ELISA to measure interleukin-6 and -8 levels and reactive oxygen species (ROS) levels were checked using H2DCFDA and MitoSox probes. Statistical analyses were performed by Two-Away ANOVA test.

  Results: SCD mice demonstrated an impairment of Glypican-1 expression in lung samples (WT: 1.51 ± 0.27, n=3; SCD: 0.20 ± 0.01, n=3). In addition, PAECs treated with Hemin in different concentrations showed an increase in ROS assessed by H2DCFDA and MitoSox probes compared to control. In addition, interleukin-6 (Hemin 20 µM - Control: 232 ± 34; SCD: 2110 ± 84) and -8 (Hemin 20 µM – Control: 119 ± 17; SCD: 877 ± 46) levels were increased by Hemin treatment. Similar to lung samples, PAECs treated with Hemin showed decreased expression of Syndecan-1 (Control: 0.95 ± 0.05, n=3; SCD: 0.22 ± 0.04, n=3).  

  Conclusions: SCD is associated with glycocalyx degradation, redox imbalance and inflammation. These abnormalities can contribute to the endothelial dysfunction characteristic of SCD.

  - The speaker desire to present this research in oral presentation.

  - Experimental research.

   

• Palavras-chave
• sickle cell disease, glycocalyx, syndecan-1, glypican-1
• Área Temática
• Apresentações Orais - Sessão IX

Voltar